TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration

News | 09. 08. 2014

TESARO

WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) — TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for oral rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).